Advertisement

Side Effects of Anabolic Androgenic Steroids: Pathological Findings and Structure–Activity Relationships

  • Andreas Büttner
  • Detlef Thieme
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 195)

Abstract

Side effects of anabolic steroids with relevance in forensic medicine are mainly due to life-threatening health risks with potential fatal outcome and cases of uncertain limitations of criminal liability after steroid administration. Both problems are typically associated with long-term abuse and excessive overdose of anabolic steroids. Side effects may be due to direct genomic or nongenomic activities (myotrophic, hepatotoxic), can result from down-regulation of endogenous biosynthesis (antiandrogenic) or be indirect consequence of steroid biotransformation (estrogenic).

Logically, there are no systematic clinical studies available and the number of causally determined fatalities is fairly limited. The following compilation reviews typical abundant observations in cases where nonnatural deaths (mostly liver failure and sudden cardiac death) were concurrent with steroid abuse. Moreover, frequent associations between structural characteristics and typical side effects are summarized.

Keywords

Side effects Heart Liver Arteriosclerosis Psychiatry 

Reference

  1. Akhter J, Hyder S, Ahmed M (1994) Cerebrovascular accident associated with anabolic steroid use in a young man. Neurology 44:2405–2406PubMedGoogle Scholar
  2. Anderson RA, Bancroft J, Wu FC (1992) The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 75:1503–1507PubMedCrossRefGoogle Scholar
  3. Applebaum-Bowden D, Haffner SM, Hazzard WR (1987) The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein2 cholesterol. Metab Clin Exp 36:949–952PubMedGoogle Scholar
  4. Arvary D, Pope HG Jr (2000) Anabolic-androgenic steroids as a gateway to opioid dependence. N Engl J Med 342:1532PubMedCrossRefGoogle Scholar
  5. Bachmann M, Sinner D (2007) Anabole steroide. BMS – Verlag pp 816Google Scholar
  6. Bahrke MS, Yesalis CE (2004) Abuse of anabolic androgenic steroids and related substances in sport and exercise. Curr Opin Pharmacol 4:614–620PubMedCrossRefGoogle Scholar
  7. Belelli D, Lambert JJ (2005) Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6:565–575PubMedCrossRefGoogle Scholar
  8. Bonetti A, Tirelli F, Catapano A, Dazzi D, Dei Cas A, Solito F, Ceda G, Reverberi C, Monica C, Pipitone S, Elia G, Spattini M, Magnati G (2008) Side effects of anabolic androgenic steroids abuse. Int J Sports Med 29:679–687Google Scholar
  9. Breuer ME, McGinnis MY, Lumia AR, Possidente BP (2001) Aggression in male rats receiving anabolic androgenic steroids: effects of social and environmental provocation. Horm Behav 40:409–418PubMedCrossRefGoogle Scholar
  10. Brower KJ (2002) Anabolic steroid abuse and dependence. Curr Psychiatry Rep 4:377–387PubMedCrossRefGoogle Scholar
  11. Brower K, Blow F, Eliopulos G, Beresford T (1989) Anabolic androgenic steroids and suicide. Am J Psychiatry 146:1075PubMedGoogle Scholar
  12. Büttner A, Sachs A, Mall G, Tutsch-Bauer E, Weis S (2001) Progressive idiopathic bilateral striato-pallido-dentate calcinosis (Fahr’s disease) in a person with anabolic steroid abuse. Leg Med 3:114–118CrossRefGoogle Scholar
  13. Catlin DH, Hatton CK (1991) Use and abuse of anabolic and other drugs for athletic enhancement. Adv Intern Med 36:399–424PubMedGoogle Scholar
  14. Changchit A, Durham S, Vore M (1990) Characterization of [3H]estradiol-17 beta-(beta-d-glucuronide) binding sites in basolateral and canalicular liver plasma membranes. Biochem Pharmacol 40:1219–1225PubMedCrossRefGoogle Scholar
  15. Chitturi S, Farrell GC (2001) Drug-induced cholestasis. Semin Gastrointest Dis 12:113–124PubMedGoogle Scholar
  16. Choi P, Parrott AC, Cowan D (1990) High-dose anabolic steroids in strength athletes: effects upon hostility and aggression. Human Psychopharm 5:349–356CrossRefGoogle Scholar
  17. Chu K, Kang DW, Kim DE, Roh JK (2001) Cerebral venous thrombosis associated with tentorial subdural hematoma during oxymetholone therapy. J Neurol Sci 185:27–30PubMedCrossRefGoogle Scholar
  18. Clark AS, Harrold EV (1997) Comparison of the effects of stanozolol, oxymetholone, and testosterone cypionate on the sexual behavior of castrated male rats. Behav Neurosci 111:1368–1374PubMedCrossRefGoogle Scholar
  19. Clark AS, Henderson LP (2003) Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci Biobehav Rev 27:413–436PubMedCrossRefGoogle Scholar
  20. Clark AS, Harrold EV, Fast AS (1997) Anabolic-androgenic steroid effects on the sexual behavior of intact male rats. Horm Behav 31:35–46PubMedCrossRefGoogle Scholar
  21. Cohen JC, Hickman R (1987) Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 64:960–963PubMedCrossRefGoogle Scholar
  22. Cohen LI, Hartford CG, Rogers GG (1996) Lipoprotein (a) and cholesterol in body builders using anabolic androgenic steroids. Med Sci Sport Exer 28:176–179Google Scholar
  23. Copeland J, Peters R, Dillon P (2000) Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. Drug Alcohol Depend 60:91–96CrossRefGoogle Scholar
  24. Daly RC, Su TP, Schmidt PJ et al (2003) Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology 28:317–331PubMedCrossRefGoogle Scholar
  25. D’Ascenzo S, Millimaggi D, Di Massimo C, Saccani-Jotti G, Botrè F, Carta G et al (2007) Detrimental effects of anabolic steroids on human endothelial cells. Toxicol Lett 169:129–136PubMedCrossRefGoogle Scholar
  26. De Piccoli B, Benettin A, Sartori F, Piccolo E (1991) Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. Int J Sports Med 12:408–412PubMedCrossRefGoogle Scholar
  27. DeLorimier A, Gordan G, Lowe R (1965) Methyltestosterone, related steroids, and liver function. Arch Intern Med 116:289–294PubMedGoogle Scholar
  28. Di Paolo M, Agozzino M, Toni C, Luciani AB, Molendini L, Scaglione M et al (2007) Sudden anabolic steroid abuse-related death in athletes. Int J Cardiol 114:114–117PubMedCrossRefGoogle Scholar
  29. Dickerman RD, Schaller F, Prather I, McConathy WJ (1995) Sudden cardiac death in a 20-year-old bodybuilder using anabolic steroids. Cardiology 86:172–173PubMedCrossRefGoogle Scholar
  30. Dickerman RD, Schaller F, Zachariah NY, McConathy WJ (1997) Left ventricular size and function in elite bodybuilders using anabolic steroids. Clin J Sport Med 7:90–93PubMedCrossRefGoogle Scholar
  31. Dubrovsky BO (2005) Steroids, neuroactive steroids and neurosteroids in psychopathology. Prog Neuropsychopharmacol Biol Psychiatry 29:169–192PubMedCrossRefGoogle Scholar
  32. DuRant RH, Vaughn RI, Ashworth CS, Newman C, Slavens G (1993) Use of multiple drugs among adolescents who use anabolic steroids. N Engl J Med 328:922–926PubMedCrossRefGoogle Scholar
  33. Ebenbichler CF, Sturm W, Gänzer H, Bodner J, Mangweth B, Ritsch A, et al (2001) Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids. Atherosclerosis 158:483–490PubMedCrossRefGoogle Scholar
  34. Eklöf A-C, Thurelius A-M, Garle M, Rane A, Sjöqvist F (2003) The anti-doping hot-line, a means to capture the abuse of doping agents in the Swedish society and a new service function in clinical pharmacology. Eur J Clin Pharmacol 59:571–577PubMedCrossRefGoogle Scholar
  35. Evans NA (2004) Current concepts in anabolic-androgenic steroids. Am J Sports Med 32:534–542PubMedCrossRefGoogle Scholar
  36. Fineschi V, Riezzo I, Centini F, Silingardi E, Licata M, Beduschi G et al (2007) Sudden cardiac death during anabolic steroid abuse: morphologic and toxicologic findings in two fatal cases of bodybuilders. Int J Legal Med 121:48–53PubMedCrossRefGoogle Scholar
  37. Frankle MA, Eichberg R, Zachariah SB (1988) Anabolic androgenic steroids and a stroke in an athlete: case report. Arch Phys Med Rehab 69:632–633Google Scholar
  38. Fröhlich J, Kullmer T, Urhausen A, Bergmann R, Kindermann W (1989) Lipid profile of body builders with and without self-administration of anabolic steroids. Eur J Appl Physiol Occup Physiol 59:98–103PubMedCrossRefGoogle Scholar
  39. Gao W, Bohl CE, Dalton JT (2005) Chemistry and structural biology of androgen receptor. Chem Rev 105:3352–3370PubMedCrossRefGoogle Scholar
  40. Giammanco M, Tabacchi G, Giammanco S, Di Majo D, La Guardia M (2005) Testosterone and aggressiveness. Med Sci Monit 11:RA136–RA145PubMedGoogle Scholar
  41. Gibbs TT, Russek SJ, Farb DH (2006) Sulfated steroids as endogenous neuromodulators. Pharmacol Biochem Behav 84:555–567PubMedCrossRefGoogle Scholar
  42. Glazer G (1991) Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch Intern Med 151:1925–1933PubMedCrossRefGoogle Scholar
  43. Grace F, Sculthorpe N, Baker J, Davies B (2003) Blood pressure and rate pressure product response in males using high-dose anabolic androgenic steroids (AAS). J Sci Med Sport 6:307–312PubMedCrossRefGoogle Scholar
  44. Graham S, Kennedy M (1990) Recent developments in the toxicology of anabolic steroids. Drug Saf 5:458–476PubMedCrossRefGoogle Scholar
  45. Hall RC, Hall RC (2005) Abuse of supraphysiologic doses of anabolic steroids. South Med J 98:550–555PubMedCrossRefGoogle Scholar
  46. Hall RCW, Hall RCW, Chapman MJ (2005) Psychiatric complications of anabolic steroid abuse. Psychosomatics 46:285–290PubMedCrossRefGoogle Scholar
  47. Halvorsen S, Thorsby PM, Haug E (2004) Acute myocardial infarction in a young man who had been using androgenic anabolic steroids. Tidsskr Nor Laegeforen 124:170–172PubMedGoogle Scholar
  48. Hartgens F, Kuipers H (2004) Effects of anabolic-androgenic steroids in athletes. Sports Med 34:513–554PubMedCrossRefGoogle Scholar
  49. Hartgens F, Cheriex EC, Kuipers H (2003) Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med 24:344–351PubMedCrossRefGoogle Scholar
  50. Hartgens F, Rietjens G, Keizer HA, Kuipers H, Wolffenbuttel BHR (2004) Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br J Sports Med 38:253–259PubMedCrossRefGoogle Scholar
  51. Haupt HA, Rovere GD (1984) Anabolic steroids: a review of the literature. Am J Sports Med 12:469–484PubMedCrossRefGoogle Scholar
  52. Hausmann R, Hammer S, Betz P (1998) Performance enhancing drugs (doping agents) and sudden death - a case report and review of the literature. Int J Legal Med 111:261–264PubMedCrossRefGoogle Scholar
  53. Herd MB, Belelli D, Lambert JJ (2007) Neurosteroid modulation of synaptic and extrasynaptic GABA(A) receptors. Pharmacol Ther 116:20–34PubMedCrossRefGoogle Scholar
  54. Hickson RC, Ball KL, Falduto MT (1989) Adverse effects of anabolic steroids. Med Toxicol Adv Drug Exp 4:254–271Google Scholar
  55. Hislop MS, St Clair Gibson A, Lambert MI, Noakes TD, Marais AD (2001) Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. Atherosclerosis 159:425–432PubMedCrossRefGoogle Scholar
  56. Hosie AM, Wilkins ME, da Silva HM, Smart TG (2006) Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 444:486–489. Epub 2006 Nov 2015PubMedCrossRefGoogle Scholar
  57. Hurley BF, Seals DR, Hagberg JM, Goldberg AC, Ostrove SM, Holloszy JO et al (1984) High-density-lipoprotein cholesterol in bodybuilders vs powerlifters. Negative effects of androgen use. JAMA 252:507–513PubMedCrossRefGoogle Scholar
  58. Ishak KG, Zimmerman HJ (1987) Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 7:230–236PubMedCrossRefGoogle Scholar
  59. Kanayama G, Cohane GH, Weiss RD, Pope HG (2003) Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem? J Clin Psychiatry 64:156–160PubMedCrossRefGoogle Scholar
  60. Karila T (2003) Adverse effects of anabolic androgenic steroids on the cardiovascular, metabolic and reproductive systems of anabolic substance abusers. Dissertation Medical Faculty, University of HelsinkiGoogle Scholar
  61. Karila TA, Karjalainen JE, Mäntysaari MJ, Viitasalo MT, Seppälä TA (2003) Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. Int J Sports Med 24:337–543PubMedCrossRefGoogle Scholar
  62. Kasikcioglu E, Oflaz H, Arslan A, Topcu B, Kasikcioglu HA, Umman B et al (2007) Aortic elastic properties in athletes using anabolic-androgenic steroids. Int J Cardiol 114:132–134PubMedCrossRefGoogle Scholar
  63. Kelley SP, Alan JK, O’Buckley TK et al (2007) Antagonism of neurosteroid modulation of native gamma-aminobutyric acid receptors by (3alpha, 5alpha)-17-phenylandrost-16-en-3-ol. Eur J Pharmacol 572:94–101PubMedCrossRefGoogle Scholar
  64. Kicman AT (2009) Biochemical and physiological aspects of endogenous androgens. In: Thieme D, Hemmersbach, P (eds) Doping in Sports, Handbook of Experimental Pharmacology 195, Springer, HeidelbergGoogle Scholar
  65. Klötz F, Garle M, Granath F, Thiblin I (2006) Criminality among individuals testing positive for the presence of anabolic androgenic steroids. Arch Gen Psychiatry 63:1274–1279PubMedCrossRefGoogle Scholar
  66. Klötz F, Petersson A, Isacson D, Thiblin I (2007) Violent crime and substance abuse: A medico-legal comparison between deceased users of anabolic androgenic steroids and abusers of illicit drugs. Forensic Sci Int 173:57–63PubMedCrossRefGoogle Scholar
  67. Kouri EM, Lukas SE, Pope HG Jr, Oliva PS (1995) Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend 40:73–79PubMedCrossRefGoogle Scholar
  68. Krieg A, Scharhag J, Albers T, Kindermann W, Urhausen A (2007) Cardiac tissue doppler in steroid users. Int J Sports Med 28:638–643PubMedCrossRefGoogle Scholar
  69. Kuipers H, Wijnen JA, Hartgens F, Willems SM (1991) Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med 12:413–418PubMedCrossRefGoogle Scholar
  70. LaBree M (1991) A review of anabolic steroids: uses and effects. J Sports Med 31:618–626Google Scholar
  71. Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF et al (2006) Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest 36:483–488PubMedCrossRefGoogle Scholar
  72. Laroche GP (1990) Steroid anabolic drugs and arterial complications in an athlete – a case history. Angiology 41:964–969PubMedCrossRefGoogle Scholar
  73. Lenders JW, Demacker PN, Vos JA, Jansen PL, Hoitsma AJ, van ’t Laar A et al (1988) Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med 9:19–23PubMedCrossRefGoogle Scholar
  74. Lippi G, Guidi G, Ruzzenente O, Braga V, Adami S (1997) Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis. Scand J Clin Lab Invest 57:507–511PubMedCrossRefGoogle Scholar
  75. Lukas SE (1996) CNS effects and abuse liability of anabolic-androgenic steroids. Annu Rev Pharmacol Toxicol 36:333–357PubMedCrossRefGoogle Scholar
  76. Luke JL, Farb A, Virmani R, Sample RHB (1990) Sudden cardiac death during exercise in a weight lifter using anabolic androgenic steroids: pathological and toxicological findings. J Forensic Sci 35:1441–1447PubMedGoogle Scholar
  77. Maravelias C, Dona A, Stefanidou M, Spiliopoulou C (2005) Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett 158:167–175PubMedCrossRefGoogle Scholar
  78. McGinnis MY, Lumia AR, Possidente BP (2002) Effects of withdrawal from anabolic androgenic steroids on aggression in adult male rats. Physiol Behav 75:541–549PubMedCrossRefGoogle Scholar
  79. McKillop G, Todd IC, Ballantyne D (1986) Increased left ventricular mass in a bodybuilder using anabolic steroids. Br J Sports Med 20:151–152PubMedCrossRefGoogle Scholar
  80. Melchert RB, Welder AA (1995) Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sport Exer 27:1252–1262Google Scholar
  81. Mellon SH, Griffin LD (2002) Neurosteroids: biochemistry and clinical significance. Trends Endocrinol Metab 13:35–43PubMedCrossRefGoogle Scholar
  82. Melnik B, Jansen T, Grabbe S (2007) Abuse of anabolic-androgenic steroids and bodybuilding acne: an underestimated health problem. Journal der Deutschen Dermatologischen Gesellschaft (JDDG) 5:110–117CrossRefGoogle Scholar
  83. Mennerick S, He Y, Jiang X et al (2004) Selective antagonism of 5alpha-reduced neurosteroid effects at GABA(A) receptors. Mol Pharmacol 65:1191–1197PubMedCrossRefGoogle Scholar
  84. Middleman AB, DuRant RH (1996) Anabolic steroid use and associated health risk behaviours. Sports Med 21:251–255PubMedCrossRefGoogle Scholar
  85. Mochizuki RM, Richter KJ (1988) Cardiomyopathy and cerebrovascular accident associated with anabolic-androgenic steroid use. Phys Sportsmed 16:109–112Google Scholar
  86. Modlinski R, Fields KB (2006) The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep 5:104–109PubMedGoogle Scholar
  87. Narducci WA, Wagner JC, Hendrickson TP, Jeffrey TP (1990) Anabolic steroids – a review of the clinical toxicology and diagnostic screening. Clin Toxicol 28:287–310CrossRefGoogle Scholar
  88. Nelson RJ, Chiavegatto S (2001) Molecular basis of aggression. Trends Neurosci 24:713–719PubMedCrossRefGoogle Scholar
  89. Nottin S, Nguyen L, Terbah M, Obert P (2006) Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue doppler imaging Am J Cardiol 97:912–915PubMedCrossRefGoogle Scholar
  90. Pálfi S, Ungureán A, Vécsei L (1997) Basilar artery occlusion associated with anabolic steroid abuse in a 17-year-old bodybuilder. Eur Neurol 37:190–191PubMedCrossRefGoogle Scholar
  91. Parkinson AB, Evans NA (2006) Anabolic androgenic steroids: a survey of 500 users. Med Sci Sport Exer 38:644–651CrossRefGoogle Scholar
  92. Pärssinen M, Kujala U, Vartiainen E, Sarna S, Seppälä T (2000) Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med 21:225–227PubMedCrossRefGoogle Scholar
  93. Pavlatos AM, Fultz O, Monberg MJ, Vootkur A, Pharmd (2001) Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin Ther 23:789–801Google Scholar
  94. Perry PJ, Kutscher EC, Lund BC et al (2003) Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J Forensic Sci 48:646–651PubMedGoogle Scholar
  95. Petersson A, Garle M, Granath F, Thiblin I (2006a) Morbidity and mortality in patients testing positively for the presence of anabolic androgenic steroids in connection with receiving medical care. A controlled retrospective cohort study. Drug Alcohol Depend 81:215–220PubMedCrossRefGoogle Scholar
  96. Petersson A, Garle M, Holmgren P, Druid H, Krantz P, Thiblin I (2006b) Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend 81:241–249PubMedCrossRefGoogle Scholar
  97. Pey A, Saborido A, Blazquez I, Delgado J, Megias A (2003) Effects of prolonged stanozolol treatment on antioxidant enzyme activities, oxidative stress markers, and heat shock protein HSP72 levels in rat liver. J Steroid Biochem Mol Biol 87:269–277PubMedCrossRefGoogle Scholar
  98. Pinna G, Costa E, Guidotti A (2005) Changes in brain testosterone and allopregnanolone biosynthesis elicit aggressive behavior. Proc Natl Acad Sci USA 102:2135–2140PubMedCrossRefGoogle Scholar
  99. Pope HG, Katz DL (1994) Psychiatric and medical effects of anabolic androgenic steroid use: a controlled study of 160 athletes. Arch Gen Psychiatry 51:375–382PubMedGoogle Scholar
  100. Pope HG Jr, Kouri EM, Hudson JI (2000a) Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 57:133–140; discussion 155–136Google Scholar
  101. Pope HG Jr, Kouri EM, Hudson JI (2000b) Effects of supraphysiologic doses of testosterone on mood and aggression in normal men. Arch Gen Psychiatry 57:133–140PubMedCrossRefGoogle Scholar
  102. Reddy DS (2004) Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol. Neuroscience 129:195–207PubMedCrossRefGoogle Scholar
  103. Rockhold RW (1993) Cardiovascular toxicity of anabolic steroids. Annu Rev Pharmacol Toxicol 33:497–520PubMedCrossRefGoogle Scholar
  104. Sachtleben TR, Berg KE, Elias BA, Cheatham JP, Felix GL, Hofschire PJ (1993) The effects of anabolic steroids on myocardial structure and cardiovascular fitness. Med Sci Sport Exer 25:1240–1245Google Scholar
  105. Sader MA, Griffiths KA, McCredie RJ, Handelsman DJ, Celermajer DS (2001) Androgenic-anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol 37:224–230PubMedCrossRefGoogle Scholar
  106. Sahraian MA, Mottamedi M, Azimi AR, Moghimi B (2004) Androgen-induced cerebral venous sinus thrombosis in a young body builder: case report. BMC Neurol 4:22PubMedCrossRefGoogle Scholar
  107. Santora LJ, Marin J, Vangrow J, Minegar C, Robinson M, Mora J et al (2006) Coronary calcification in body builders using anabolic steroids. Prev Cardiol 9:198–201PubMedCrossRefGoogle Scholar
  108. Schumacher M, Liere P, Akwa Y et al (2008) Pregnenolone sulfate in the brain: a controversial neurosteroid. Neurochem Int 52:522–540PubMedCrossRefGoogle Scholar
  109. Shahidi NT (2001) A review of the chemistry, biological action, and clinical applications of anabolic-androgenic steroids. Clin Ther 23:1355–1390PubMedCrossRefGoogle Scholar
  110. Simon P, Striegel H, Aust F, Dietz K, Ulrich R (2006) Doping in fitness sports: estimated number of unreported cases and individual probability of doping. Addiction 101:1640–1644PubMedCrossRefGoogle Scholar
  111. Slikker W Jr, Vore M, Bailey JR, Meyers M, Montgomery C (1983) Hepatotoxic effects of estradiol-17 beta-D-glucuronide in the rat and monkey. J Pharmacol Exp Ther 225:138–143PubMedGoogle Scholar
  112. Sloane DE, Lee CW (2007) Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 120:654–658PubMedCrossRefGoogle Scholar
  113. Socas L, Zumbado M, Pérez-Luzardo O, Ramos A, Pérez C, Hernández JR et al (2005) Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 39:e27PubMedCrossRefGoogle Scholar
  114. Soe K, Soe M, Gluud C (1992) Liver pathology associated with the use of anabolic-androgenic steroids. Liver 12:73–79PubMedGoogle Scholar
  115. Stimac D, Milic S, Dintinjana RD, Kovac D, Ristic S (2002) Androgenic/Anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol 35:350–352PubMedCrossRefGoogle Scholar
  116. Su TP, Pagliaro M, Schmidt PJ et al (1993) Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 269:2760–2764PubMedCrossRefGoogle Scholar
  117. Sullivan ML, Martinez CM, Gennis P, Gallagher EJ (1998) The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis 41:1–15PubMedCrossRefGoogle Scholar
  118. Talih F, Fattal O, Malone D Jr (2007) Anabolic steroid abuse: psychiatric and physical costs. Cleve Clin J Med 74:341–352PubMedCrossRefGoogle Scholar
  119. Thiblin I, Petersson A (2005) Pharmacoepidemiology of anabolic androgenic steroids: a review. Fundam Clin Pharmacol 19:27–44PubMedCrossRefGoogle Scholar
  120. Thiblin I, Runeson B, Rajs J (1999) Anabolic androgenic steroids and suicide. Ann Clin Psychiatry 11:223–231PubMedGoogle Scholar
  121. Thiblin I, Lindquist O, Rajs J (2000) Cause and manner of death among users of anabolic androgenic steroids. J Forensic Sci 45:16–23PubMedGoogle Scholar
  122. Trenton AJ, Currier GW (2005) Behavioural manifestations of anabolic steroid use. CNS Drugs 19:571–595PubMedCrossRefGoogle Scholar
  123. Urhausen A, Albers T, Kindermann W (2004) Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart 90:496–501PubMedCrossRefGoogle Scholar
  124. Uzych L (1992) Anabolic-androgenic steroids and psychiatric-related effects: a review. Can J Psychiatry 37:23–28PubMedGoogle Scholar
  125. Vore M, Hadd H, Slikker W Jr (1983a) Ethynylestradiol-17 beta D-ring glucuronide conjugates are potent cholestatic agents in the rat. Life Sci 32:2989–2993PubMedCrossRefGoogle Scholar
  126. Vore M, Montgomery C, Meyers M (1983b) Steroid D-ring glucuronides: characterization of a new class of cholestatic agents. Drug Metab Rev 14:1005–1019PubMedCrossRefGoogle Scholar
  127. Webb OL, Laskarzewski PM, Glueck CJ (1984) Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. Metabolism 33:971–975PubMedCrossRefGoogle Scholar
  128. Wu FCW (1997) Endocrine aspects of anabolic steroids. Clin Chem 43:1289–1292PubMedGoogle Scholar
  129. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V (1999) Psychosexual effects of three doses of testosterone cycling in normal men. Biol Psychiatry 45:254–260PubMedCrossRefGoogle Scholar
  130. Yeater R, Reed C, Ullrich I, Morise A, Borsch M (1996) Resistance trained athletes using or not using anabolic steroids compared to runners: effects on cardiorespiratory variables, body composition, and plasma lipids. Br J Sports Med 30:11–14PubMedCrossRefGoogle Scholar
  131. Yesalis CE, Bahrke MS (1995) Anabolic-androgenic steroids. Current issues. Sports Med 19:326–340PubMedCrossRefGoogle Scholar
  132. Zmuda JM, Thompson PD, Dickenson R, Bausserman LL (1996) Testosterone decreases lipoprotein(a) in men. Am J Cardiol 77:1245–1248CrossRefGoogle Scholar
  133. Zuliani U, Bernardini B, Catapano A, Campana M, Cerioli G, Spattini M (1989) Effects of anabolic steroids, testosterone, and HGH on blood lipids and echocardiographic parameters in body builders. Int J Sports Med 10:62–66PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  • Andreas Büttner
    • 1
  • Detlef Thieme
  1. 1.Institute of Legal MedicineRostockGermany

Personalised recommendations